First external quality assurance of antibody diagnostic for SARS-new coronavirus

Matthias Niedrig*, Katrin Leitmeyer, Wilina Lim, Malik Peiris, John S. Mackenzie, Maria Zambon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

To confirm an infection with the new coronavirus (SARS-CoV) causing the severe acute respiratory syndrome (SARS) diagnostic assays for detection of SARS-CoV specific antibody are necessary. To evaluate the diagnostic performance of laboratories an external quality assurance (EQA) study was performed in 2004. Participating laboratories (9/20) correctly detected anti-SARS antibodies in serum samples without false positive results in an immunofluorescence assay. In contrast, only 4/13 laboratories detected most of the anti-SARS antibody positive samples without false positive results using enzyme immunoassays (EIA) and/or immunoblot. The overall results clearly demonstrate that serological diagnosis of SARS-CoV remains at an early stage of development, with further technical improvements required, particularly with respect to the use of SARS specific EIAs.

Original languageEnglish
Pages (from-to)22-25
Number of pages4
JournalJournal of Clinical Virology
Volume34
Issue number1
DOIs
Publication statusPublished - Sept 2005

Bibliographical note

Funding Information:
The work was partially supported by the EC grant SPC 20002396. The author especially thanks Dr. Angela Merianos, the SARS focal point at WHO, Geneva for providing information and support.

Keywords

  • Antibody diagnostic
  • EQA
  • External quality assurance
  • SARS

Fingerprint

Dive into the research topics of 'First external quality assurance of antibody diagnostic for SARS-new coronavirus'. Together they form a unique fingerprint.

Cite this